Brain scans reveal how alcohol craving drug works
NCT ID NCT06269627
First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 4 times
Summary
This study looks at how the drug acamprosate affects brain function in people with moderate to severe alcohol use disorder. Researchers will use EEG to measure brain waves in 48 adults who stay in the clinic for about 3 weeks. Half get acamprosate, half get a placebo, and brain activity is compared to see if the drug reduces craving-related signals.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALCOHOL USE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a brain zapping headset curb relapse in addiction?
- Can a smartphone app tame Alcohol-Related liver disease?
- Calm in a room: can sensory therapy soothe the mind?
- Can a brief alcohol intervention improve mental health treatment?
- Smartphone support for sobriety: a trial tests digital tools in black communities
- Emergency room could be the starting point for alcohol addiction treatment